Association Between NAT2 Polymorphisms and Prostate Cancer
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 2
Abstract
Background NAT2 enzyme involved in bioconversion of aromatic amines, heterocyclic arylamines and certain drugs into electrophilic ions that can be important initiators in tumorigenesis process. Objectives The aim of this study was to assess the possible association between NAT2 polymorphisms (857 G > A, 481 T > C, and 590 G > A) and risk of prostate cancer (PC). Methods Totally, 207 benign prostate hyperplasia (BPH) and 147 PC Iranian patients were evaluated. NAT2 genotypes were detected by restriction fragment length polymorphism (RFLP). Multiple logistic regression models were used to estimate the odds ratios for the association between presence of each genotype and developing PC. Results For NAT2 G857A, the frequency of AA and AG genotypes was lower among PC patients compared to those without it (1.01% vs. 0 and 55.88% vs. 54.55%, respectively; P = 0.7). For NAT2 T481c, the odds ratios for the association of TT and CT genotypes with PC were 0.65 and 0.55, respectively, which were not statistically significant (P = 0.5 and P = 0.09, respectively). For NAT2 G590a, both AA (11.11% vs. 12.87%) and AG (45.83% vs. 52.48%) genotypes were significantly more common among PC patients compared to BPC patients (P = 0.008). However, none of the relevant odds ratios were statistically significant (OR = 2.2, P = 0.2 and OR = 1.72, P = 0.1, respectively). Among PC patients, CT genotype of T481C caused more than 4-fold significant increase in the risk of developing advanced stages of PC. Conclusions Our study represented credible evidence that carrying G857A, G590A and T481C polymorphisms of NAT2 may not affect developing PC, its grading or invasion, but heterozygote genotype of T481C polymorphism (Rapid acetylator) can be associated with more advanced stages of cancer earlier in life. Further longitudinal studies with larger sample sizes are needed to more precisely assess the genetic risk factors of PC.
Authors and Affiliations
Mandana Hasanzad, Seyed Amir Mohsen Ziaei, Vahideh Montazeri, Mahdi Afshari, Seyed Hamid Jamaldini, Mahdieh Imani, Mahshid Sattari, Leila Hashemian, Seyed Rouhollah Kalantar Moaetamed, Mohammad Samzadeh
Keywords
Related Articles
- EP ID EP237298
- DOI 10.5812/ijcp.5716
- Views 68
- Downloads 0
Investigation of Stigma Phenomenon in Cancer: A Grounded Theory Study
Background Adjustment to cancer as a stressful event is affected by bio-psycho-social factors. Objectives This study aimed to investigate stigma phenomenon, the process of formati...
Association Between NAT2 Polymorphisms and Prostate Cancer
Background NAT2 enzyme involved in bioconversion of aromatic amines, heterocyclic arylamines and certain drugs into electrophilic ions that can be important initiators in tumorige...
Cannabis sativa Extract Reduces Cytoskeletal Associated Proteins in Breast Cancer Cell Line
Background: Previous studies suggested that Cannabis sativa has anti-cancer properties influencing tumor size and metastasis properties. Microtubule associated proteins (MAPs) such as tau binds to the microtubules and le...
Antioxidant Supplements and Breast Cancer: A Systematic Review and Meta-Analysis
Context: Breast cancer is the second most common type of cancer worldwide and the most frequent one among women. Some studies suggest a favorable role of antioxidants on breast cancer, but this is still controversial. O...
The Effect of Radiation Therapy on Hearing Loss in Patients with Head and Neck Cancer
Background: Radiotherapy is one of the important components of head and neck cancer (HNC) treatment. This treatment method may cause a variety of side effects like oral problems, swelling, and hearing loss. Objectives:...